Advertisement

Organisation › Details
Novo Seeds
Novo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. Novo A/S is not a corporate strategic fund; Novo A/S invests for financial rather than strategic returns. Novo A/S is active in both Europe and North America. The Novo A/S venture investments are managed by a team of four Partners in Copenhagen, one in London and three in San Francisco. With an evergreen structure, Novo A/S annually invests approximately EUR 200 million through Novo Ventures, Novo Seeds, and Novo Growth Equity. In total Novo A/S has more than EUR 15 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S. *
![]() |
Start | 2011-05-03 existent |
Group | Novo Group (Group) | |
![]() |
Industry | venture capital |
Industry 2 | LIFE SCIENCES | |
![]() |
Person | Christgau, Stephan (Eir Ventures 202007– before Novo Seeds + Osteologix) |
Person 2 | Grotkjær, Thomas (Novo Group 201809 Principal at Novo Seeds) | |
![]() |
Region | Hellerup |
Country | Denmark | |
Street | 19 Tuborg Havnevej c/o Novo A/S | |
City | 2900 Hellerup | |
Tel | +45-3527-6500 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for �About Section�: Delenex Therapeutics AG. (5/3/11). "Press Release: Delenex Extends Its A Round to CHF 30.2 Million. Thomas Dyrberg from Novo A/S Joins the Board of Directors". Schlieren. | ||
Record changed: 2020-12-16 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for Novo Group (Group)
- [1] Novo Holdings A/S. (12/14/20). "Press Release: Novo Holdings Creates New Rare Bleeding Disorder Company, Hemab". Copenhagen....
- [2] BioInnovation Institute (BII). (12/8/20). "Press Release: The Novo Nordisk Foundation Establishes BioInnovation Institute as an Independent Foundation". Copenhagen....
- [3] Novo Holdings A/S. (11/23/20). "Press Release: ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of a Novel Lupus Treatment". Copenhagen....
- [4] Novo Holdings A/S. (11/9/20). "Press Release: Novo Ventures-incubated Rare Disease Company, Stargazer Pharmaceuticals, Enters Ph2 Development and Announces $57m Series A Financing". Boston, MA....
- [5] Emisphere Technologies, Inc.. (11/6/20). "Press Release: Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion". Roseland, NJ....
- [6] The Protein Brewery B.V.. (11/3/20). "Press Release: The Protein Brewery Raises € 22 Million Series A investment". Breda....
- [7] Evotec SE. (10/13/20). "Press Release: Mubdala Investment Company and Novo Holdings A/S Invest €250m in Evotec SE". Hamburg....
- [8] Novo Holdings A/S. (9/17/20). "Press Release: Novo Ventures Co-leads US$83m Series C Financing in Lava Therapeutics". Copenhagen....
- [9] Gibbs, Matthew [CipherBio = SVB]. (9/14/20). "News: The Funding Flow Between European and US Life Sciences"....
- [10] Evotec SE. (8/18/20). "Press Release: Evotec and Novo Nordisk Form Strategic Alliance to Develop Novel Therapies for Kidney Diseases". Hamburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top